Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and platelets

Current Vascular Pharmacology

Volumn 3, Issue 1, 2005, Pages 41-53

  Wanstall, Janet C ^a   Homer, Kerry L ^a   Doggrell, Sheila A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Doggrell Biomedical Communications   (New Zealand)

Author keywords

cGMP independent; NO; NO donors; Platelets; Vascular relaxation growth apoptosis

Indexed keywords

1 [N (3 AMINOPROPYL) N [4 (3 AMINOPROPYLAMMONIO)BUTYL]AMINO]DIAZEN 1 IUM 1,2 DIOLATE; 1 N METHYL N [6 (N METHYLAMMONIOHEXYL)AMINO]DIAZEN 1 IUM 1,2 DIOLATE; 1 PROPAMINE(3 HYDROXY 2 NITROSO 1 PROPYLHYDRAZINE)DIAZEN 1 IUM 1,2 DIOLATE; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 (N,N DIETHYLAMINO)DIAZEN 1 IUM 1,2 DIOLATE; 3 (3 CHLORO 2 METHYLPHENYL) 5 (2 PROPYNYLAMINOCARBONYLIMINO) 1,2,3,4 OXATRIAZOLE; 3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; 4 ETHYL 2 HYDROXYIMINO 5 NITRO 3 HEXENAMIDE; 4H 8 BROMO 1,2,4 OXADIAZOLO[3,4 D]BENZ[B][1,4]OXAZIN 1 ONE; 6 ANILINO 5,8 QUINOLINEQUINONE; 8 BROMO CYCLIC GMP; CYCLIC GMP; GLYCERYL TRINITRATE; GUANYLATE CYCLASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LINSIDOMINE; METHYLENE BLUE; N ACETYL S NITROSOCYSTEINE; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; NS 2028; OXAZINE DERIVATIVE; S NITROSOCYSTEINE; S NITROSOGLUTATHIONE; S NITROSOHOMOCYSTEINE; S NITROSOTHIOL; TRIAZENE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOCONSTRICTOR AGENT;

APOPTOSIS; ATHEROSCLEROSIS; BLOOD VESSEL; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; ISCHEMIA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; AUSTRALIA; BLOOD PLATELETS; BLOOD VESSELS; CYCLIC GMP; ENZYME INHIBITORS; GUANYLATE CYCLASE; HUMANS; NITRIC OXIDE; NITRIC OXIDE DONORS;

EID: 11844277081     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161052773933     Document Type: Review

References (100)

1. Murrell W. Nitroglycerin as a remedy for angina pectoris. Lancet 1879; I: 80-1.
2. Murad F, Mittal CK, Arnold WP, Katsuki S, Kimura H. Guanylate cyclase: activation by azide, nitro compounds, nitric oxide and hydroxyl radical and inhibition by haemoglobin and myoglobin. Adv Cyclic Nucleotide Res 1978; 9: 145-58.
3. Gruetter CA, Barry BK, McNamara DB, Gruetter DY, Kadowitz PJ, Ignarro L. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res 1979; 5: 211-24.
4. Ignarro LJ, Edwards JC, Gruetter DY, Barry BK, Gruetter CA. Possible involvement of S-nitrosothiols in the activation of guanylate cyclase by nitroso compounds. FEBS Lett 1980; 110: 275-78.
5. Diamond J, Blisard KS. Effects of stimulant and relaxant drugs on tension and cyclic nucleotide levels in canine femoral artery. Mol Pharmacol 1976; 12: 668-92.
6. Katsuki S, Arnold W, Mittal C, Murad F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerine and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J Cyclic Nucleotide Res 1977; 3: 23-35.
7. Kukovetz WR, Holzmann S, Wurm A, Poch G. Evidence for cyclic GMP-mediated relaxant effects of nitro-compounds in coronary smooth muscle. Naunyn Schmiedeberg's Arch Pharmacol 1979; 310: 129-38.
8. Gruetter CA, Gruetter DY, Lyon JE, Kadowitz PJ, Ignarro LJ. Relationship between cyclic guanosine 3′:5′-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: effects of methylene blue and methemoglobin. J Pharmacol Exp Ther 1981; 219: 181-16.
9. Diamond J, Janis RA. Increases in cyclic GMP levels may not mediate relaxant effects of sodium nitroprusside, verapamil and hydralazine in rat vas deferens. Nature 1978; 271: 472-3.
10. Diamond J, Chu EB. Possible role for cyclic GMP in endothelium-dependent relaxation of rabbit aorta by acetylcholine. Comparison with nitroglycerin. Res Commun Chem Pathol Pharmacol 1983; 41: 369-81.
11. Rapoport RM, Murad F. Effect of cyanide on nitrovasodilator-induced relaxation, cyclic GMP accumulation and guanylate cyclase activation. Eur J Pharmacol 1984; 104: 61-70.
12. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994; 368: 850-3.
13. Ca) in smooth muscle cells isolated from rat mesenteric artery. Br J Pharmacol 1998; 124: 1131-40.
14. Homer KL, Wanstall JC. Cyclic GMP-independent relaxation of rat pulmonary artery by spermine NONOate, a diazeniumdiolate nitric oxide donor. Br J Pharmacol 2000; 131: 673-82.
15. +-ATPase activity by nitric oxide: a cGMP-independent effect. Am J Physiol 1994; 266: H2146-51.
16. 2+ in myocytes from guinea-pig small mesenteric arteries. J Physiol 2002; 539: 25-39.
17. Ellershaw DC, Greenwood IA, Large WA. Dual modulation of swelling-activated chloride current by NO and NO donors in rabbit portal vein myocytes. J Physiol 2000; 528: 15-24.
18. Alonso-Galicia M, Sun CW, Falck JR, Harder DR, Roman RJ. Contribution of 20-HETE to the vasodilator actions of nitric oxide in renal arteries. Am J Physiol 1998; 275: F370-8.
19. + channel activity and vascular tone in renal arterioles. Circ Res 1998; 83: 1069-79.
20. Alonso-Galicia M, Hudetz AG, Shen H, Harder DR, Roman RJ. Contribution of 20-HETE to vasodilator actions of nitric oxide in the cerebral microcirculation. Stroke 1999; 30: 2727-34.
21. Nozik-Grayck E, McMahon TJ, Huang YC, Dieterle CS, Stamler JS, Piantadosi CA. Pulmonary vasoconstriction by serotonin is inhibited by S-nitroglutathione. Am J Physiol Lung Cell Mol Physiol 2002; 282: L1057-65.
22. 2+' uptake activity can account for the reduced response to NO, but not sodium nitroprusside, in hypercholesterolaemic rabbit aorta. Circulation 2001; 104:1040-5.
23. 2+ stores. Circ Res 1999; 84: 201-9,
24. Homer KL, Wanstall JC. Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate. Br J Pharmacol 2002; 137: 1071-81.
25. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, del Soldato P. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 2001; N 98: 4202-8.
26. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 1993; 45: 367-74.
27. Brune B, Schmidt KU, Ullrich V. Activation of soluble guanylate cyclase by carbon monoxide and inhibition by superoxide anion. Eur J Biochem 1990; 192: 633-8.
28. Huie RE, Padjama S. The reaction of NO with superoxide. Free Radic Res Commun 1993; 18: 195-9.
29. Wolin MS, Cherry PD, Rodenburg JM, Messina EJ, Kaley G. Methylene blue inhibits vasodilation of skeletal muscle arterioles to acetylcholine and nitric oxide via the extracellular generation of superoxide anion. J Pharmacol Exp Ther 1990; 254: 872-6.
30. Schmidt MJ, Sawyer BD, Truex LL, Marshall WS, Fleisch JH. LY 83583: An agent that lowers intracellular levels of cyclic guanosine 3′,5′-monophosphate. J Pharmacol Exp Ther 1985; 232: 764-9.
31. Mülsch A, Busse R, Liebau S, Forstermann U. LY 83585 interferes with the release of endothelium-derived relaxing factor and inhibits soluble guanylate cyclase. J Pharmacol Exp Ther 1988; 247:283-8.
32. Luo D, Das S, Vincent SR. Effects of methylene blue and LY83583 on neuronal nitric oxide synthase and NADPH-diaphorase. Eur J Pharmacol 1995; 290: 247-51.
33. Cherry PD, Omar HA, Farrell KA, Stuart JS, Wolin MS. Superoxide anion inhibits cGMP-associated bovine pulmonary arterial relaxation. Am J Physiol 1990; 259: H1056-62.
34. Kontos HA, Wei EP. Hydroxyl radical-dependent inactivation of guanylate cyclase in cerebral arterioles by methylene blue and by LY83583. Stroke 1993; 24: 427-34.
35. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, May B. Potent and selective inhibition of nitric oxide-sensitive guarylyl cyclase by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 1995; 48:184-8.
36. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B. Characterization of 1H-[1,2,4]Oxadiazolo[4,3-a quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 1996; 50:1-5.
37. Zhao Y, Brandish PE, DiValentin M, Schelvis JP, Babcock GT. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 2000; 39: 10848-54.
38. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Dailey-Usmar, VM. el al. cGMP mediates the vascular and platelet actions of nitric oxide: Confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci USA 1996; 93: 1480-5.
39. Feelisch M, Kotsonis P, Siebe J, Clement B, Schmidt HH. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-α]quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Mol Pharmacol 1999; 56: 243-53.
40. Brunner F, Schmidt K, Nielsen EB, Mayer B. Novel guanylyl cyclase inhibitor potently inhibits cyclic GMP formation accumulation in endothelial cells and relaxation of bovine pulmonary artery. J Pharmacol Exp Ther 1996; 277: 48-53.
41. Olesen SP, Drejer J, Axelsson O, Moldt P, Bang L, Nielsen-Kudsk JE, et al. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol 1998; 123: 299-309.
42. Marshall JJ, Wei EP, Kontos HA. Independent blockade of cerebral vasodilation from acetylcholine and nitric oxide. Am J Physiol 1988; 255:H847-54.
43. Weisbrod RM, Griswold MC, Yaghoubi M, Komalavilas P, Lincoln TM, Cohen RA. Evidence that additional mechanisms to cyclic GMP mediate the decrease in intracellular calcium and relaxation of rabbit aortic smooth muscle to nitric oxide. Br J Pharmacol 1998; 125: 1695-707.
44. Tseng CM, Tabrizi-Fard MA, Fung HL. Differential sensitivity among nitric oxide donors toward ODQ-mediated inhibition of vascular relaxation. J Pharmacol Exp Ther 2000; 292: 737-42.
45. Wanstall JC, Jeffery TK, Gambino A, Lovren F, Triggle CR. Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion. Br J Pharmacol 2001; 134: 463-72.
46. Plane F, Wiley KE, Jeremy JY, Cohen RA, Garland CJ. Evidence that different mechanisms underlie smooth muscle relaxation to nitric oxide and nitric oxide donors in the rabbit isolated carotid artery. Br J Pharmacol 1998; 123: 1351-8.
47. Onoue H, Katusic ZS. The effect of 1H-[1,2,4]oxadiazolo[4,3,-α]quinoxalin-1-one (ODQ) and charybdotoxin (CTX) on relaxations of isolated cerebral arteries to nitric oxide. Brain Res 1998; 785: 107-13.
48. Faraci FM, Sobey CG. Role of soluble guanylate cyclase in dilator responses of the cerebral microcirculation. Brain Res 1999; 821: 368-73.
49. Plane F, Hurrell A, Jeremy JY, Garland CJ. Evidence that potassium channels make a major contribution to SIN-1-evoked relaxation of rat isolated mesenteric artery. Br J Pharmacol 1996; 119: 1557-62.
50. Plane F, Sampson LJ, Smith JJ, Garland CJ. Relaxation to authentic nitric oxide and SIN-1 in rat isolated mesenteric arteries: variable role for smooth muscle hyperpolarization. Br J Pharmacol 2001; 133: 665-72.
51. Sampson LJ, Plane F, Garland CJ. Involvement of cyclic GMP and potassium channels in relaxation evoked by the nitric oxide donor, diethylamine NONOate, in the rat small isolated mesenteric artery. Naunyn-Schmiedeberg's Arch Pharmacol 2001; 354:220-5.
52. Sand AE, Andersson E, Fried G. Effects of nitric oxide donors and inhibitors of nitric oxide signalling on endothelin- and serotonin-induced contractions in human placental arteries. Acta Physiol Scand 2002; 174: 217-23.
53. Homer KL, Fiore SA, Wanstall JC. Inhibition by 1H-[1,2,4]oxadiazolo[4,3,-α]quinoxalin-1-one (ODQ) of responses to nitric oxide-donors in rat pulmonary artery: influence of the mechanism of nitric oxide generation. J Pharm Pharmacol 1999; 51: 135-9.
54. Trottier G, Triggle CR, O'Neill SK, Loutzenhiser R. Cyclic GMP-dependent and cyclic GMP-independent actions of nitric oxide on the renal afferent arteriole. Br J Pharmacol 1998; 125: 563-9.
55. Lovren F, Triggle C. Nitric oxide and sodium-prusside-induced relaxation of the human umbilical artery. Br J Pharmacol 2000; 131: 521-9.
56. Buus NH, Simonsen U, Pilegaard HK, Mulvany MJ. Nitric oxide, prostanoid and non-NO, non-prosanoid involvement in acetylcholine relaxation of isolated human small arteries. Br J Pharmacol 2000; 129: 184-92.
57. Pauvert O, Marthan R, Savineau J. NO-induced modulation of calcium-oscillations in pulmonary vascular smooth muscle. Cell Calcium 2000; 27: 329-38.
58. Bolz S-S, Vogel L, Sollinger D, Derwand R, de Wit C, Loirand G, et al. Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation 2002; 107: 3081-7.
59. Sandner P, Kornfield M, Ruan X, Arendshorst WJ, Kurtz A. Nitric oxide/cAMP interactions in the control of rat renal vascular resistance. Circ Res 1999; 84: 186-92.
60. 2+-activated potassium channels in smooth muscle cells of the human corpus cavernosum. Urol Res 2001; 29: 359-65.
61. Hashitani H, Fukuta H, Dickens EJ, Suzuki H. Cellular mechanisms of nitric oxide-induced relaxation of corporal smooth muscle in the guinea-pig. J Physiol 2002; 538: 573-81.
62. Kanagy NL, Charpie JR, Dananberg J, Webb RC. Decreased sensitivity to vasoconstrictors in aortic rings after acute exposure to nitric oxide. Am J Physiol 1996; 271: H253-60.
63. Terluk MR, da Silva-Santos JE, Assreuy J. Involvement of soluble guanylate cyclase and calcium-activated potassium channels in the long-lasting hyperresponsiveness to phenylephrine induced by nitric oxide in rat aorta. Naunyn-Schmiedeberg's Arch Pharmacol 2000; 261: 477-83.
64. Alencar JL, Lobysheva I, Geffard M, Sarr M, Schott C, Schini-Kerth VB, et al. Role of S-nitrosation of cysteine residues in long-lasting inhibitory effect of nitric oxide on arterial tone. Mol Pharmacol 2003; 63: 1148-58.
65. Sogo N, Campanella C, Webb DJ, Megson IL. S-Nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br J Pharmacol 2000; 131: 1236-44.
66. Da Silva-Santos JE, Assreuy J. Long-lasting changes of rat blood pressure to vasoconstrictors and vasodilators induced by nitric oxide donor infusion: involvement of potassium channels. J Pharmacol Exp Ther 1999; 290: 380-7.
67. Alencar JL, Lobysheva I, Chalupsky K, Geffard, M, Nepveu F., Stoclet JC, et al. S-nitrosating nitric oxide donors induce long-lasting inhibition of contraction in isolated arteries. J Pharmacol Exp Ther 2003; 307: 152-9.
68. Tsui DYY, Gambino A, Wanstall JC. S-nitrosocaptopril: in vitro characterization of pulmonary vascular effects in rats. Br J Pharmacol 2003; 138: 855-64.
69. Hogg N. Biological and clinical potential of S-nitrosothiols. Free Radic Biol Med 2000; 28: 1478-86.
70. Najibi S, Cowan CL, Palacino JJ, Cohen RA. Enhanced role of potassium channels in relaxations to acetylcholine in hypercholesterolemic rabbit carotid artery. Am J Physiol 1994; 266: H2061-7.
71. Mingone CJ, Gupte SA, Lesaki T, Wolin MS. Hypoxia enhances a cGMP-independent nitric oxide relaxing mechanism in pulmonary arteries. Am J Physiol 2003; 285: L296-304.
72. Garg UC, Hassid A. Nitric oxide generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-7.
73. Dhaunsi GS, Matthews C, Kaur K, Hassid A. NO increases protein tyrosine phosphatase activity in smooth muscle cells: relationship to antimitogenesis. Am J Physiol 1997; 272: H1342-9.
74. Kariya K, Kawahara Y, Araki S, Fukuzaki H, Taka Y. Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells. Atherosclerosis 1989; 80: 143-7.
75. 2+ mobilisation by cyclic AMP and GMP in rabbit aortic smooth-muscle cells. Biochem J 1992; 288: 527-32.
76. Southgate K, Newby AC. Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis 1990; 82: 113-23.
77. Lähteenmäki T, Sievi E, Vapaatalo H. Inhibitory effects of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives on vascular smooth muscle cell mitogenesis and proliferation in vitro. Br J Pharmacol 1998; 125: 402-8.
78. Sandirasegarane L, Charles R, Bourbon N, Kester M. NO regulates PDGF-induced activation of PKB but not ERK in A7r5 cells: implications for vascular growth arrest. Am J Physiol 2000; 279: C225-35.
79. Young DV, Serebryanik D, Janero DR, Tam SW. Suppression of proliferation of human coronary artery smooth muscle cells by the nitric oxide donor, S-nitrosoglutathione, is cGMP-independent. Mol Cell Biol Res Commun 2000;4:32-6.
80. Ishida A, Sasaguri T, Miwa Y, Kosaka C, Taba Y, Abumiya T. Tumor suppressor p53 but not cGMP mediates NO-induced expression of p21 (Waf1/Cip1/Sdi1) in vascular smooth muscle cells. Mol Pharmacol 1999; 56: 938-46.
81. Kibbe MR, Li J, Nie S, Watkins SC, Lizonova A, Kovesdi I, el al. Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p%# and cylcic guanosine monophosphate. J Vasc Surg 2000; 31: 1214-28.
82. Filippi S, Crescioli C, Vannelli GB, Fazzini A, Natali A, Riffaud JP, el al. Effects of NCX 4050, a new NO donor, in rabbit and human corpus carvernosum. Int J Androl 2003; 26: 101-8.
83. Heller R, Polack T, Gräbner R, Till U. Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP. Atherosclerosis 1999; 144: 49-57.
84. Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin 1 receptors. J Clin Invest 1995; 96: 141-9.
85. Nishio E, Fukushima K, Shiozaki M, Watanabe Y. Nitric oxide donor SNAP induces apoptosis in smooth muscle cells through cGMP-independent mechanism. Biochem Biophys Res Commun 1996; 221: 163-8.
86. Wang BY, Ho HK, Lin PS, Schwarzacher SP, Pollman MJ, Gibbons GH, et al. Regression of atherosclerosis: role of nitric oxide and apoptosis. Circulation 1999; 99: 1236-41.
87. -/-vascular smooth muscle cells. Am J Physiol Cell Physiol 2002; 282: C625-34.
88. Sata M, Kakoki M, Nagata D, Nishimatsu H, Suzuki E, Aoyagi T, et al. Adrenomedullin and nitric oxide inhibit human endothelial cell apoptosis via a cyclic GMP-independent mechanism. Hypertension 2000; 36: 83-8.
89. Shen YH, Wang XL, Wilcken DE. Nitric oxide induces and inhibits apoptosis through different pathways. FEBS Lett 1998; 433: 125-31.
90. Zhang R, Wang L, Zhang L, Chen J, Zhu Z, Zhang Z, et al. Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke. Circ Res 2003; 92: 308-313.
91. Gordge MP, Hothersall JS, Noronha-Dutra AA. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione. Br J Pharmacol 1998; 124: 141-8.
92. 2 synthesis in human blood platelets. FEBS Lett 1999; 442: 162-6.
93. Sogo N, Magid KS, Shaw CA, Webb DJ, Megson IL. Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP mechanisms. Biochem Biophys Res Commun 2000; 279: 412-9.
94. Beghetti M, Sparling C, Cox PN, Stephens D, Adatia I. Inhaled nitric oxide inhibits platelet aggregation and elevates plasma but not intraplatelet cGMP in healthy human volunteers. Am J Physiol 2003; 285: H637-42.
95. Kibbe M, Billiar T, Tzeng E. Inducible nitric oxide synthase and vascular injury. Cardiovasc Res 1999; 43: 650-7.
96. Kloss S, Bouloumie A, Mulsch A. Aging and chronic hypertension decrease expression of rat aortic soluble guanylate cyclase. Hypertension 2000; 35: 43-7.
97. Ruetten H, Zabel U, Linz W, Schmidt HH. Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res 1999; 85: 534-541.
98. Papapetropoulos A, Abou-Mohamed G, Marczin N, Murad F, Caldwell RW, Caravas JD. Downregulation of nitrovasodilator-induced cyclic GMP accumulation in cells exposed to endotoxin or interleukin-1 beta. Br J Pharmacol 1996; 118: 1359-66.
99. Scott WS, Nakayama DK. Eschericia coli lipopolysaccharide downregulates soluble guanylate cyclase in pulmonary artery smooth muscle. J Surg Res 1998; 80: 309-14.
100. Courtois E, Marques M, Barrientos A, Casado S, Lopez-Farre A. Lead-induced downregulation of soluble guanylyl cyclasse in isolated rat aortic segments mediated by reactive oxygen species and cyclooxygenase-2. J Am Soc Nephrol 2003; 14: 1464-70.